AstraZeneca to buy rare-disease specialist Alexion for $39bn
13 December 2020 - 16:50
London — AstraZeneca, one of the drugmakers leading the fight against Covid-19, highlighted where its growth will come from after the pandemic with a $39bn deal for rare-disease specialist Alexion Pharmaceuticals.
The proposed cash-and-stock acquisition will add treatments for uncommon blood and immunological disorders to the portfolio of Cambridge, UK-based AstraZeneca, which had spent years paring away older and less profitable products to focus on cancer...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.